[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100627574":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":16,"locations":22,"responsibleParty":48,"collaborators":10,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":54,"sex":59,"minAge":60,"maxAge":10,"enrollmentInfo":61,"targetDuration":64,"studyType":65,"phases":10,"briefSummary":66,"conditions":67,"keywords":70,"overallStatus":75,"whyStopped":10,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Central Hospital, Nancy, France","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Critically ill patients with acute brain injury",null,"Patients with severe acute brain injury defined by a Glasgow coma scale \\\u003C or = 8, admitted to the intensive care unit and needed invasive mechanical ventilation for at least 48 hours.",[13],{"name":14,"affiliation":5,"role":15},"Emmanuel NOVY, MD,PhD","STUDY_DIRECTOR",[17],{"name":18,"role":19,"phone":20,"phoneExt":10,"email":21},"Maureen Steib, MD","CONTACT","+33 3 83 85 10 45","m.steib@chru-nancy.fr",[23,36],{"facility":24,"status":10,"city":25,"state":26,"zip":27,"country":28,"countryCode":29,"cosmosGeoPoint":30,"geoPoint":35,"contacts":10},"CHRU de Nancy - Hôpital Central","Nancy","Lorraine","54000","France","FR",{"type":31,"coordinates":32},"Point",[33,34],6.18496,48.68439,{"lat":34,"lon":33},{"facility":37,"status":10,"city":25,"state":38,"zip":27,"country":28,"countryCode":29,"cosmosGeoPoint":39,"geoPoint":41,"contacts":42},"CHRU Nancy - Hopital Central","Meurthe-et-Moselle",{"type":31,"coordinates":40},[33,34],{"lat":34,"lon":33},[43,45],{"name":44,"role":19,"phone":20,"phoneExt":10,"email":21},"Maureen STEIB",{"name":46,"role":19,"phone":10,"phoneExt":10,"email":47},"Viviane MARTIN, PhD","v.martin3@chru-nancy.fr",{"type":49,"investigatorFullName":50,"investigatorTitle":51,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","STEIB Maureen","Assistante Spécialiste","100627574","pkpd-target-attainment-of-ceftriaxone-for-the-prevention-of-early-ventilator-associated-pneumonia-in-neurologically-injured-patients-100627574",false,"NCT07450404","PK\u002FPD Target Attainment of Ceftriaxone for the Prevention of Early Ventilator-associated Pneumonia in Neurologically Injured Patients","NeuroPKVAP","Inclusion Criteria:\n\n* 18 years or older\n* Admitted in intensive care unit for acute brain injury, including traumatic brain injury and cerebral vascular disease\n* Glasgow coma scale inferior to 12\n* Orotracheal intubation in first 12 hours of admission\n* Needed of invasive mechanical ventilation for at least 48 hours\n\nExclusion Criteria:\n\n* Acute brain injury related to tumoral or infectious process\n* Antibiotic therapy administered before acute brain injury for an other pathology\n* Patients with a risk of multiresistance bacteria contamination (stay in a risk area in the past 3 months, antibiotic therapy with fluoroquinolone or betalctamine in the past 3 months, hospitalization in last month before admission, documented contaminationwith multiresistance bacteria, immunodepression)\n* Patients with hish risk of death in the first 48 hours\n* Patients with a beta-lactams reported allergy","ALL","18 Years",{"count":62,"type":63},60,"ESTIMATED","28 Days","OBSERVATIONAL","Critically ill patients admitted for acute brain injury are exposed to many heath-care associated infections such as ventilator associated pneumoniae (VAP). The PROHYVAP study, published in 2024 reported that a single dose of CEFTRIAXONE as an antibiotic prophylaxis could reduce the incidence of early VAP (VAP that occured between day 2 and day 7 of mechanical ventilation).\n\nHowever, patients with acute brain injury also presented frequently augmented renal clearance (ARC), which could affect the pharmacokinetic and pharmacodynamic target attainment (PK\u002FPD) of antibiotic prophylaxis.\n\nThis study aims to analyse the PK\u002FPD target attainment after one dose of CEFTRIAXONE in critically ill patients with acute brain injury and to describe the effect of ARC on PK\u002FPD target attainment during early VAP.",[68,69],"Early Ventilator Associated Pneumonia","Acute Brain Injuries",[71,72,73,74],"Antibiotic prophylaxis","ventilator associated pneumonia","augmented renal clearance","PK\u002FPD target attainment","NOT_YET_RECRUITING","2026-03-02",{"date":78,"type":79},"2026-03-04","ACTUAL",{"date":81,"type":63},"2026-03-01",{"date":83,"type":63},"2027-10-01",{"name":5,"class":6},2]